Treatment Compliance with Fixed-Dose Combination of Vildagliptin-Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational StudyReport as inadecuate




Treatment Compliance with Fixed-Dose Combination of Vildagliptin-Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study - Download this document for free, or read online. Document in PDF available to download.

International Journal of Endocrinology - Volume 2015 2015, Article ID 251485, 5 pages -

Research Article

Novartis Hellas S.A., 12th klm National Road 1, Metamorfosis, 14451 Athens, Greece

Foundation for Economic and Industrial Research IOBE, 11 Tsami Karatatsi Street, 11742 Athens, Greece

University Hospital of Ioannina, Stavros Niarchos Avenue, 45500 Ioannina, Greece

Received 26 August 2014; Accepted 26 September 2014

Academic Editor: Ilias Migdalis

Copyright © 2015 Grigorios Rombopoulos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To evaluate the differences in treatment compliance with vildagliptin-metformin fixed-dose versus free-dose combination therapy in patients with type 2 diabetes mellitus T2DM in Greece. Design. Adult patients with T2DM, inadequately controlled with metformin monotherapy, 850 mg bid, participated in this 24-week, multicenter, observational study. Patients were enrolled in two cohorts: vildagliptin-metformin fixed-dose combination group A and vildagliptin metformin free-dose combination group B. Results. 659 patients were enrolled, 360 were male, with mean BMI 30.1, mean T2DM duration 59.6 months, and mean HbA1c at baseline 8%; 366 patients were assigned to group A and 293 to group B; data for 3 patients was missing. In group A, 98.9% of patients were compliant with their treatment compared to 84.6% of group B. The odds ratio for compliance in group A versus B was OR 18.9 95% CI: 6.2, 57.7; . In group A mean HbA1c decreased from 8.1% at baseline to 6.9% at the study end and from 7.9% to 6.8% in group B. Conclusions. Patients in group A were more compliant than patients in group B. These results are in accordance with international literature suggesting that fixed-dose combination therapies lead to increased compliance to treatment.





Author: Grigorios Rombopoulos, Magdalini Hatzikou, Athanasios Athanasiadis, and Moyses Elisaf

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents